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Abstract: Phosphatidic acid (PA) is a bioactive phospholipid capable of regulating key biological
functions, including neutrophil respiratory burst, chemotaxis, or cell growth and differentiation.
However, the mechanisms whereby PA exerts these actions are not completely understood. In this
work, we show that PA stimulates myoblast proliferation, as determined by measuring the incor-
poration of [3H]thymidine into DNA and by staining the cells with crystal violet. PA induced the
rapid phosphorylation of Akt and ERK1/2, and pretreatment of the cells with specific small interferin
RNA (siRNA) to silence the genes encoding these kinases, or with selective pharmacologic inhibitors,
blocked PA-stimulated myoblast proliferation. The mitogenic effects of PA were abolished by the
preincubation of the myoblasts with pertussis toxin, a Gi protein inhibitor, suggesting the implication
of Gi protein-coupled receptors in this action. Although some of the effects of PA have been asso-
ciated with its possible conversion to lysoPA (LPA), treatment of the myoblasts with PA for up to
60 min did not produce any significant amount of LPA in these cells. Of interest, pharmacological
blockade of the LPA receptors 1 and 2, or specific siRNA to silence the genes encoding these receptors,
abolished PA-stimulated myoblast proliferation. Moreover, PA was able to compete with LPA for
binding to LPA receptors, suggesting that PA can act as a ligand of LPA receptors. It can be concluded
that PA stimulates myoblast proliferation through interaction with LPA1 and LPA2 receptors and
the subsequent activation of the PI3K/Akt and MEK/ERK1-2 pathways, independently of LPA
formation.
Keywords: phosphatidic acid; lysophosphatidic acid; myoblast proliferation; lysophosphatidic
acid receptors
1. Introduction
Phosphatidic acid (PA) is the precursor of triacylglycerol (TAG), which is the main form
of energy store in humans, and constitutes the original building block from which many
phospholipids are synthesized [1,2], thereby playing a relevant role in cell architecture.
Later, it was demonstrated that PA is a second messenger capable of regulating a variety of
intracellular signaling pathways and cell functions.
PA can be synthesized by three major pathways: (a) the acylation of lysophosphatidic
acid (LPA, initially formed by the esterification of sn-1 by glycerol 3-phosphate acyltrans-
ferase) by LPA acyltransferases, (b) the phosphorylation of diacylglycerol (DAG) by DAG
kinase, and (c) the hydrolysis of membrane phospholipids, namely phosphatidylcholine
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(PC), by phospholipase D (PLD) activities. Whilst LPA acyltransferases are involved in the
biosynthesis of structural PA in the endoplasmic reticulum (ER), PA produced by DAG
kinase or PLDs is implicated in the regulation of key physiological and pathological cell
process. These include apoptosis, cytoskeletal rearrangement, chemotaxis, membrane
trafficking, differentiation, micropinocytosis, secretory vesicle formation, cell growth, and
tumor progression [3–10].
In mammalian cells, PA exerts its biological effects through distinct mechanisms.
In this context, the cone-shaped geometry and negative charge of the molecule enable
PA to interact with different proteins or enzymes to regulate their catalytic activities and
their association with different membrane compartments. This is, for instance, the case
for some GTP-binding proteins of the ADP ribosylation factor (Arf) and Rho families of
homomeric G proteins [11]. Among the main signaling regulators, PA has been shown to
control the activity of various protein kinase C (PKC) isoforms to promote the recruitment
and activation of the proto-oncogene kinase Raf [12], and to regulate the activity of the
mammalian target of rapamycin (mTOR), which are all involved in the regulation of cell
proliferation [13]. In addition to kinases, PA also modulates the activity of a variety of
phosphatases, including protein phosphatase 1 (PP1), which is involved in many cellular
activities such as glycogen metabolism, the processing of RNA and the regulation of the cell
cycle [10]. Although PA is a signaling molecule in its own right, some of its biological effects
can be exerted by its conversion to LPA by phospholipase A2 activity [14]. Concerning
muscle biology, the proliferation of myogenic cells is a critical process in skeletal muscle
formation during embryogenesis, or the regeneration of adult muscle after injury. Muscle
regeneration results from the activation, proliferation, and fusion of myogenic precursor
cells called satellite cells. If left unrepaired, muscle damage can lead to loss of muscle
mass, locomotive deficiency, and in severe cases, death. An important effector that leads to
muscle regeneration is the mechanical stimulation. This plays a major role in the regulation
of skeletal muscle mass and its maintenance contributes to prevent disease and to improve
life quality. Some studies have shown that the mechanical stimulation of skeletal muscle
and exercise promote an increase in PA concentration [15–18]. Additionally, PA is found in
plasma and is present in a number of commonly consumed food sources [19]. However,
the mechanisms by which PA regulates cell proliferation are not well understood.
In the present work, we demonstrate that PA stimulates myogenic cell proliferation
through interaction with the LPA receptors, LPA1 and LPA2, and the subsequent activation
of the phosphatidylinositol 3 kinase (PI3-K)/Akt (also known as protein kinase B) and
extracellularly regulated kinases (ERK1/2) signaling pathways.
2. Results
2.1. Phosphatidic Acid Promotes Myoblast DNA Synthesis and Proliferation
In the present work, we show that PA stimulates DNA synthesis and cell division in
C2C12 myoblasts, a murine satellite cell line commonly employed to investigate skeletal
muscle cell biology. The stimulation of DNA synthesis was concentration dependent,
reaching maximal values at 15 µM PA after 16 h of incubation (Figure 1A). Likewise, the
treatment of C2C12 cells with exogenous phospholipase D (exPLD), which generates PA at
the plasma membrane of cells, also stimulated DNA synthesis in the myoblasts (Figure 1B).
Cell proliferation was also determined by staining the myoblasts with crystal violet, which
is a reliable assay to estimate the cell number of adherent cells [20]. Treatment with PA for
16 h significantly increased cell proliferation, with optimal stimulation being attained at
15 µM PA (Figure 1C).
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Figure 1. Phosphatidic acid (PA) stimulates C2C12 myoblast proliferation. Approximately 40% 
confluent C2C12 myoblasts were serum-starved for 24 h in Dulbecco’s modified eagle’s medium 
(DMEM) supplemented with 0.1% bovine serum albumin (BSA). A. Cells were treated for 16 h 
with PA at the indicated concentrations. [3H]Thymidine incorporation into DNA was measured as 
described in the Materials and Methods section. Data are expressed relative to the control (Ctrl) 
value without agonist and are the means ± SEM of 3 independent experiments performed in tripli-
cate. (***p <0.001). B. Cells were treated for 16 h with 15 μM PA or with exogenous phospholipase 
D (exPLD) (1 unit/ ml). [3H]Thymidine incorporation into DNA was measured as indicated in the 
Materials and Methods section. Data are expressed relative to the control value (Ctrl) without ago-
nist and are the means ± SEM of 4 independent experiments performed in triplicate. (**p <0.01; ***p 
<0.001). C. Cells were treated for 24 h with PA at the indicated concentrations. Cell proliferation 
was determined by staining the myoblasts with crystal violet as described in the Materials and 
Methods section. Data are expressed relative to the control value without agonist and are the 
means ± SEM of 6 independent experiments performed in triplicate. (*p <0.05; ***p <0.001). 
2.2. Phosphatidic Acid Stimulates the PI3-K/Akt and MEK/ERK1-2 Pathways in Myoblasts. 
Implication in PA-Stimulated Myoblast Proliferation. 
To investigate the mechanisms by which PA exerts is mitogenic actions, we tested 
the effects of this phospholipid on the stimulation of PI3-K/Akt and MEK/ERK1-2, which 
are two major signaling pathways implicated in the regulation of cell proliferation by 
growth factors [21,22]. The treatment of C2C12 myoblasts with PA caused a rapid and 
Figure 1. Phosphatidic acid (PA) stimulates C2C12 myoblast proliferation. Approximately 40% confluent C2C12 myoblasts were serum-starved for 24 h in Dulbecco’s modified eagle’s
medium (DMEM) supplemented with 0.1% bovine serum albumin (BSA). (A) ells were treated fo 16 h with PA at the indi ated concentrations. [3H]Thymidine incorporation into DNA
was measured as described in the Materials and Methods section. Data are expressed relative to the control (Ctrl) value without agonist and are the means ± SEM of 3 independent
experiments performed in triplicate. (*** p < 0.001). (B) Cells were treated for 16 h with 15 µM PA or with exogenous phospholipase D (exPLD) (1 unit/mL). [3H]Thymidine incorporation
into DNA was measured as indicated in the Materials and Methods section. Data are expressed relative to the co trol value (Ctrl) without agonist and are the means ± SEM of 4
independent experiments performed in triplicate. (** p < 0.01; *** p < 0.001). (C) Cells were treated for 24 h with PA at the indicated concentrations. Cell proliferation was determined by
staining the myoblasts with crystal violet as described in the Materials and Methods section. Data are expressed relative to the control value ithout agonist and are the means ± SEM of 6
independent experiments performed in triplicate. (* p < 0.05; *** p < 0.001).
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2.2. Phosphatidic Acid Stimulates the PI3-K/Akt and MEK/ERK1-2 Pathways in Myoblasts.
Implication in PA-Stimulated Myoblast Proliferation
To investigate the mechanisms by which PA exerts is mitogenic actions, we tested the
effects of this phospholipid on the stimulation of PI3-K/Akt and MEK/ERK1-2, which
are two major signaling pathways implicated in the regulation of cell proliferation by
growth factors [21,22]. The treatment of C2C12 myoblasts with PA caused a rapid and time
dependent phosphorylation of Akt (at Ser 473), which is a kinase downstream of PI3-K
activation (Figure 2A,B). To test whether this pathway is involved in the mitogenic effect of
PA, the myoblasts were preincubated with selective inhibitors of PI3-K or Akt and DNA
synthesis was determined after stimulation with PA. Figure 2, panels C to F, shows that the
selective PI3-K inhibitor LY294002, or the blockade of Akt activity with 10-DEBC, a specific
inhibitor of this kinase, substantially reduced the incorporation of [3H]thymidine into DNA
and the increase in cell number that were elicited by PA. Likewise, the preincubation of
these cells with specific siRNAs to silence the genes encoding PI3-K or Akt1 completely
blocked the stimulation of DNA synthesis by PA, suggesting that the PI3-K/Akt1 pathway
is implicated in the mitogenic action of PA. Knockdown of Akt2 or Akt3 were without
effect, indicating that Akt1 is the relevant isoform involved in this pathway (Figure 2G).
We also observed that PA induced the rapid phosphorylation of ERK1-2, which are
MAPKs downstream of MEK activation (Figure 3A,B). To evaluate the implication of this
pathway in the mitogenic actions of PA, the selective MEK inhibitor PD98059 was used.
Figure 3 (panels C and D) shows that both the stimulation of DNA synthesis and the
increase in cell number were completely inhibited by PD98059. Moreover, the treatment
of the myoblasts with specific siRNA to silence the genes encoding ERK1-2 completely
blocked PA-stimulated DNA synthesis, suggesting that the MEK/ERK1-2 pathway is also
relevant in this process. By contrast, the preincubation of the myoblasts with SB21091
or SP600125, which selectively inhibit the MAPKs p38 and JNK, respectively, did not
significantly alter the mitogenic effect of PA in these cells (Figure 3C,D). Likewise, the
preincubation of these cells with specific siRNAs to silence the genes encoding ERK1 or
ERK2 completely blocked the stimulation of DNA synthesis by PA, suggesting that the
MEK/ERK1-2 pathway is also implicated in the mitogenic action of PA (Figure 3E).
Another relevant observation in this work was that the stimulation of myoblast
proliferation was completely abolished by the pretreatment of the myoblasts with pertussis
toxin (Ptx), an inhibitor of heterotrimeric GTP binding proteins of the Gi family of proteins
(Figure 4A,B), suggesting the implication of Gi protein-coupled receptors in this process.
Moreover, Ptx completely blocked the rapid phosphorylation of Akt and ERK1-2 induced
by PA (Figure 4C–E), further indicating that the PI3-K/Akt and MEK/ERK1-2 pathways
are relevant for the stimulation of myoblast proliferation by this phospholipid.
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lysates were analyzed by western blotting as described in the Materials and Methods section. Phosphorylation of Akt was 
determined with an antibody specific to phospho-Akt (Ser 473). Equal loading of protein was monitored using a specific 
antibody to total Akt. Panel A corresponds to a representative blot of three independent experiments. B. Results of scan-
ning densitometry of the exposed film showing the p-Akt/total Akt ratio. Data are expressed relative to the control value 
without agonist and are the mean ± SEM of 3 independent experiments performed in triplicate. (**p <0.01; ***p <0.001). C. 
C2C12 myoblasts were preincubated for 30 min with 1 μM LY 294002 and then treated with 15 μM PA for 16 h. [3H]Thy-
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the control value without agonist and are the mean ± SEM of 3 independent experiments performed in triplicate. (**p <0.01, 
control versus PA-treated cells, #p <0.05; PA-treated cells versus PA-treated cells in the presence of the inhibitor). D. Cells
were treated as in panel C. Cell proliferation was determined by staining the myoblasts with crystal violet as described in 
the Materials and Methods section. Results are expressed relative to the control value without agonist and are the mean ± 
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cells versus PA-treated cells in the presence of the inhibitor). E. C2C12 cells were preincubated for 30 min with 1 μM 10-
DEBC and then treated with 15 μM PA for 16 h. [3H]Thymidine incorporation was measured as described in the Materials 
and Methods section. Results are expressed relative to the control value without agonist and are the mean ± SEM of 3 
independent experiments performed in triplicates. (**p <0.01, control versus PA-treated cells, #p <0.05; PA-treated cells
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Figure 2. Involvement of the PI3-K/Akt pathway in PA-stimulated myoblast proliferation. Myoblasts
were serum-starved for 24 h in DMEM supplemented with 0.1% BSA. (A) The cells were challenged
with 15 µM PA at th indicated times. C ll lysates w e analyzed by wester blotting as described in
the Materials and Methods section. Phosphorylation of Akt was determined with an antibody specific
to phospho-Akt (Ser 473). Equal loading of protein was monitored using a specific antibody to total
Akt. Panel A corresponds to a representative blot of three independent experiments. (B) Results of
scanning densitometry of the exposed film showing the p-Akt/tot l Akt ratio. Data are expressed
relative to the control value without agonist and are the mean ± SEM of 3 independent experiments
performed in triplicate. (** p < 0.01; *** p < 0.001). (C) C2C12 myoblasts were preincubated for 30 min
with 1 µM LY 294002 and then treated with 15 µM PA for 16 h. [3H]Thymidine incorporation was
measured as described i the Mate ials and Methods section. Results re expressed relative to the control
value without agonist and are the mean± SEM of 3 independent experiments performed in triplicate.
(** p < 0.01, control versus PA-treated cells, # p < 0.05; PA-treated cells versus PA-treated cells in the
presence of the inhibitor). (D) Cells were treated as in panel C. Cell proliferation was determined by
staining the myoblasts with crystal violet as described in the Materials and Methods section. Results
are xpressed relative to th control value without agonist n re the mean± SEM of 3 in pendent
experiments performed in triplicate. (* p < 0.05, control versus PA-treated cells, # p < 0.05; PA-treated
cells versus PA-treated cells in the presence of the inhibitor). (E) C2C12 cells were preincubated for
30 min with 1 µM 10-DEBC and then treated with 15 µM PA for 16 h. [3H]Thymidine incorporation
was measured as described in the Materials and Methods section. Results are expressed relative to the
control value without agonist and are the mean ± SEM of 3 independent experiments performed in
triplicates. (** p < 0.01, control versus PA-treated cells, # p < 0.05; PA-treated cells versus PA-treated cells
in the presence of the inhibitor). (F) Cells were treated as in E. Cell proliferation was determined by
staining the myoblasts with crystal violet as described in the Materials and Methods section. Results
are expressed relative to the control value without agonist and are the mean± SEM of 3 independent
experiments performed in triplicate. (* p < 0.05, control versus PA-treated cells, # p < 0.05; PA-treated cells
versus PA-treated cells in the presence of the inhibitor). (G) C2C12 cells were preincubated for 5 h with
negative (scrambled) siRNA, or with specific PI3K, Akt1, Akt2, or Akt3 siRNA (40 nM in all cases), prior
to stimulation with 15 µM PA, as indicated. [3H]Thymidine incorporation was measured as described in
the Materials and Methods section. Results are expressed relative to the control value without agonist
and are the mean± SEM of 3 independent experiments performed in triplicate. (* p < 0.05 control versus
PA-treated cells, # p < 0.05; PA-treated cells versus PA-treated cells in the presence of the corresponding
siRNA).
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Figure 3. Involvement of MEK/ERK 1/2, but not p38 or JNK in PA-stimulated myoblast proliferation. Myoblas s w e serum starved and maintained in DMEM supplemented with 0.1%
BSA for 24 h before addition of agonists. (A) The cells we challenged with 15 µM PA at the indicated tim poin s. Cell lysates were analyzed by western blotting as described in the
Materials and Methods section. Phosphorylation of ERK1/2 was determined with an antibody specific to phospho-ERK1/2. Equal loading of protein was monitored using a specific
antibody to total ERK1/2. Panel A shows a representative blot of three independent experiments. (B) Results of scanning densitometry of the exposed film showing the p-ERK/total ERK
ratio. Data are expressed relative to the control value without agonist and are the mean ± SEM of 3 independent experiments performed in triplicate. (*** p < 0.001). (C) C2C12 cells
were preincubated for 30 min with 10 µM PD98059 to inhibit MEK, 5 µM SB239063 to inhibit p38 or 1 µM SP600125 to inhibit JNK, and were then treated with 15 µM PA, or vehicle for
16 h. [3H]Thymidine incorporation was measured as described in the Materials and Methods section. Results are expressed relative to the control value without agonist and are the
mean ± SEM of 3 independent experiments performed in triplicate. (* p < 0.05, control versus PA-treated cells, # p < 0.05; PA-treated cells versus PA-treated cells in the presence of the
inhibitor). (D) Cells were treated as in panel C. Cell proliferation was determined by staining the myoblasts with crystal violet as described in the Materials and Methods section. Results
are expressed relative to the control value without agonist and are the mean ± SEM of 3 independent experiments performed in triplicate. (* p < 0.05, control versus PA-treated cells, # p <
0.05; PA-treated cells versus PA-treated cells in the presence of the inhibitor); ** p < 0.01, control versus PA-treated cells in the presence of SP600126; p < 0.05, control versus PA-treated cells
in the presence of SB202190. (E) C2C12 cells were pre-treated for 5 h with negative (scrambled) siRNA, or with specific ERK1 or ERK2 siRNA (40 nM in all cases), prior to stimulation with
15 µM PA, as indicated. [3H]Thymidine incorporation was measured as described in the Materials and Methods section. Results are expressed relative to the control value without agonist
and are the mean ± SEM of 3 independent experiments performed in triplicate. (* p < 0.05, control versus PA-treated cells, # p < 0.05; PA-treated cells versus PA-treated cells in the presence
of the corresponding siRNA).
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2.3. Phosphatidic Acid Stimulates Myoblast Proliferation Through Interaction with the LPA
Receptors LPA1 and LPA2
These findings suggested that PA might be acting through interaction with a Gi protein-
coupled receptor to elicit its mitogenic effects. Since a specific receptor for PA has not yet
been identified, we hypothesized that PA might act through interaction with any of the LPA
receptors that are expressed in the myoblasts. In this connection, RT-PCR studies revealed
the presence of LPA receptor mRNAs in satellite cells [23] and in C2C12 myoblasts [24].
Of note, contrary to LPA1 and LPA2 receptors, the LPA4 receptor was implicated in a
reduction in Akt and ERK1-2 phosphorylation rather than in their enhancement, and
this receptor was coupled to Gq, G12/13 and Gs, but not to Gi proteins [25]. Hence, the
intervention of LPA4 in PA-stimulated myoblast proliferation could be ruled out. To test
the possible implication of LPA1 in this process, the selective inhibitor VPC32183 was
used. This inhibitor was able to block both PA-stimulated DNA synthesis (Figure 5A) and
cell proliferation (Figure 5B). Moreover, the phosphorylation of Akt and ERK1-2 was also
inhibited by the VPC32183 inhibitor (Figure 5C–E).
These findings suggest that both LPA1 and LPA2 receptors are implicated in the
mitogenic actions of PA in myoblasts. To confirm that PA was able to bind to LPA receptors,
radioligand binding assays using [3H]-labeled LPA and myoblast cell membranes were
performed (see Materials and Methods). Figure 7A shows that there was competition for
the specific binding of [3H]-labeled LPA by unlabeled LPA, whose IC50 (concentration of
competing ligand that displaces 50% of the specific binding of the radioligand, [3H]-LPA)
was 116.14 ± 3.14 µM. Of note, PA was able to also potently displace bound [3H]-LPA from
myoblast membranes with an IC50 of 207.97± 2.21 µM. However, sphingosine-1-phosphate,
a lysophosphosphingolipid that is structurally similar to LPA, and ceramide-1-phosphate,
which is structurally similar to PA, were unable to displace bound [3H]-LPA from the
myoblast membranes (Figure 7B).
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Figure 4. Pertussis toxin inhibits PA-stimulated myoblast proliferation and Akt and ERK1/2 phospho-
rylation. Myoblasts were serum-starved in DMEM supplemented with 0.1% BSA for 24 h. (A) Cells
were preincubated for 16 h with 0.5 µg/mL pertussis toxin (Ptx) and then further treated with 15 µM
PA or vehicle for 16 h, as indicated. [3H]Thymidine incorporation was measured as described in the
Materials and Methods section. Results are expressed relative to the control value without agonist
and are the mean ± SEM of 3 independ nt experiments erform d in triplicat . (** p < 0.01, control
versus PA-treated cells, ## p < 0.01; PA-treated cells versus PA-treated cells in the presence of Ptx).
(B) Cells were treated as in panel A. Cell proliferation was determined by staining the myoblasts with
crystal violet as described in the Materials and Methods section. Results are expressed relative to the
control value without agonist and are the mean ± SEM of 3 independent experiments performed in
triplicate. (* p < 0.05, control versus PA-treated cells, # p < 0.05; PA-treated cells versus PA-treated
cells in the presence of Ptx). (C) C2C12 cells were preincubated for 16 h with 0.5 µg/mL Ptx. The
myoblasts were then challeng d with 15 µM PA r vehicle for 5 min, as indicat d. Cell lysates were
anal zed by western b otting as described in the Mate ials a d Methods section. Phosp oryla i n
of Akt (Ser473) and ERK were determined using specific antibodies to phospho-Akt (P-Akt), or
phospho-ERK1/2 (P-ERK1/2). Equal loading of protein was monitored using specific antibodies
to total Akt and ERK1/2. Panel C shows a representative blot of three independent experiments.
(D,E) Results of scanning densitometry of the exposed films. Data are expressed as arbitrary units of
intensity relative to the control values in the absence of agonist or Ptx (Ctrl) and are the mean ± SEM
of 3 replicate experiments. (* p < 0.05; ** p < 0.01; control versus PA-treated cells, # p < 0.05, ## p <
0.01; PA-treated cells versus PA-treated cells in the presence of Ptx, as indicated).
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<0.05, ###p <0.001; PA-treated cells versus PA-treated cells in the presence of VPC32183, as indicated). 
Figure 5. Inhibition of PA-stimulated myoblast proliferation and Akt and ERK1/2 phosphorylation
by the lysoPA (LPA) receptor antagonist VPC32183. Myoblasts were serum-starved in DMEM sup-
lemented with .1% BSA for 24 h. (A) The cells were preincubated for 30 min with 5 µM V C32183
and were then challenged with 15 µM PA or 15 µM LPA for 16 h, as indicated. [3H]Thymidine
incorporation was measured as described in the Materials and Methods section. Results are ex-
pressed relative to the control value without agonist and are the mean ± SEM of 3 independent
experiments perform d in triplicate. (* p < 0.05, co trol versu PA or LPA-treat d c lls, # p < 0.05;
PA or LPA-treated cells versus PA or LPA-treated cells in the presence of VPC32183). (B) Cells were
treated as in panel A. Cell proliferation was determined by staining the myoblasts with crystal violet
as described in the Materials and Methods section. Results are expressed relative to the control value
withou gonist and are th mea ± SEM of 3 ndependent experiment performed. Cont ol versus
PA-treated cells; ** p < 0.01, control versus LPA-treated cells; # p < 0.05; PA- or LPA-treated cells
versus PA- or LPA-treated cells in the presence of VPC32183). (C) Cells were preincubated with 5
µM VPC32183 for 30 min and then treated with 15 µM PA for 5 min. Cell lysates were analyzed by
western blotting as described in th Materials and Meth ds section. Phosphorylation of Akt and
ERK1/2 was determined using specific antibodies against phospho-Akt (P-Akt) or phospho-ERK1/2
(P-ERK1/2). Equal loading of protein was monitored using specific antibodies to total Akt and total
ERK1/2. Panel C shows a representative blot of three independent experiments. (D,E) Results of
scanning densitometry of the exposed films. Data are expressed as arbitrary units of intensity relative
to the control siRNA values in the absence of agonist or inhibitor (Ctrl) and are the mean ± SEM of 3
replicate experiments. (* p < 0.05; ** p < 0.01; control versus PA-treated cells, # p < 0.05, ### p < 0.001;
PA-treated cells versus PA-treated cells in the presence of VPC32183, as indicated).
In addition, specific siRNA to silence the gene encoding the LPA1 receptor abolished
PA-stimulated DNA synthesis, and this was also the case when specific siRNA to silence
LPA2 was used (Figure 6A). The silencing of the LPA1 and LPA2 receptors also blocked the
phosphorylation of Akt and ERK1-2 (Figure 6B–D).
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These findings suggest that both LPA1 and LPA2 receptors are implicated in the mi-
togenic actions of PA in myoblasts. To confirm that PA was able to bind to LPA receptors, 
radioligand binding assays using [3H]-labeled LPA and myoblast cell membranes were 
performed (see Materials and Methods). Figure 7A shows that there was competition for 
the specific binding of [3H]-labeled LPA by unlabeled LPA, whose IC50 (concentration of 
competing ligand that displaces 50% of the specific binding of the radioligand, [3H]-LPA) 
was 116.14 ± 3.14 μM. Of note, PA was able to also potently displace bound [3H]-LPA from 
myoblast membranes with an IC50 of 207.97 ± 2.21 μM. However, sphingosine-1-phos-
phate, a lysophosphosphingolipid that is structurally similar to LPA, and ceramide-1-
Figure 6. Implication of LPA1 and LPA2 receptors in PA-induced DNA synthesis and Akt and
ERK phosphorylation. Myoblasts were preincubated for 5 h with negative (scrambled) siRNA (Neg
siRNA) or with specific LPA1 or LPA2 siRNA (40 nM in all cases), as indicated. Transfected cells
were maintained in DMEM with 10% fetal bovine serum (FBS) for 48 h and were then serum-starved
in DMEM supplemented with 0.1% BSA for 24 h. (A) Cells were treate with 15 µM PA or v hicle for
16 h, as indicated. [3H]Thymidine incorpor tion was me sured as escribed in the Materials and
Meth ds section. Results are expressed relative to the control value without agonist an are the mean
± SEM of 3 independent experiments performed in triplicate. (* p < 0.05, control versus PA-treated
cells, # p < 0.05; PA-treated cells versus PA-treated cells in the presence of siRNA). (B) Cells were
treated as above and then stimulated for 5 min with 15 µM PA or vehicle as indicated. Cell lysates were
analyzed by western blotting as described in the Materials and Methods section. Phosphorylation
of Akt and ERK1/2 was determined using specific antibodies to phospho-Akt (P-Akt) or phospho-
ERK1/2 (P-ERK1/2). Equal loading of protein was monitored using specific antibodies to total Akt
or ERK1/2. Panel B shows a representative blot of three independent experiments. (C,D) Results
of scanning densitometry of the exposed films. Data are expressed as arbitrary units of intensity
relative to the control siRNA values in the absence of agonist (Ctrl) and are the mean ± SEM of 3
replicate experiments. (* p < 0.05; ** p < 0.01; c ntrol versus PA-trea ed cells, # p < 0.05, ## p < 0.01,
### p < 0.001; PA-treated cells versus PA-tre ted cells in the pres nce of the corresponding siRNA, as
indicated).
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Figure 7. PA competes with LPA for binding to LPA receptors. (A) Myoblast membranes were
incubated with 10 µM [3H]LPA in the presence of the indicated c ncentrations of unlab led PA or
LPA, as indicated. Non-specific bindi g was measured in the absence cell of membranes. Results
are the mean ± SEM of three independent experiments performed in triplicate. Radioactivity of
filter-bound radionuclide was quantified by liquid scintillation counting, as indicated in the Materials
and Methods section. (B) The competition binding assays were performed with 10 µM [3H]LPA in
the presence of 400 µM PA, 400 µM LPA, 400 µM S1P or 400 µM C1P, as indicated. Non-specific
binding was measured in the absence of myoblast membranes. Results are the mean ± SEM of
three independent experiments performed in triplicate. (** p < 0.01). Radioactivity of filter-bound
radionuclide was quantified by liquid scintillation counting.
2.4. PA Stimulates Myoblast Proliferation in the Absence of LPA Formation
Some previous studies suggested that PA exerts its biological effects through conver-
sion to LPA by cytosolic PLA2 (cPLA2) activity, or that the PA samples used in experiments
might have been contaminated with LPA [26]. However, the preincubation of the myoblasts
with arachidonyl trifluoromethyl ketone (AACOCF3), Palmityl trifluoromethyl ketone (PA-
COCF3) or with pyrrophenone, which selectively inhibit cPLA2 activities, neither blocked
PA-stimulated DNA synthesis (Figure 8A) nor cell proliferation (Figure 8B). In addition,
the incubation of the myoblasts with [14C] phosphatidic acid for up to 1 h showed no
conversion of PA into LPA (Figure 8C), thereby ruling out a possible intervention of LPA in
the rapid phosphorylation of Akt and ERK1-2 by PA, which takes place in a few minutes
(Figures 2 and 3). Moreover, analysis of the PA samples used in experiments by thin layer
chromatography rendered no detectable amount of LPA, in agreement with the compound
supplier, who warrants a purity of 98% of the commercial PA samples. Some experiments
were also performed in the presence of specific inhibitors of autotaxin, which is the most
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important enzyme for LPA production and generates most of the extracellular LPA [27,28].
Autotaxin is a lysophospholipase D enzyme that would efficiently convert any possible
lysophosphatidylcholine (LPC) that might be present in the PA samples into LPA. However,
the autotaxin inhibitor HA-130 at 300 nM, which is a concentration over 10-fold higher than
its IC50 (28 nM) and was shown to potently inhibit transendothelial migration of naïve T
lymphocytes [29], did not significantly alter PA-stimulated myoblast proliferation (Figure
8D). Additionally, the autotaxin inhibitor PF-8380 (300 nM), which significantly reduced
basal myoblast proliferation, did not alter the mitogenic effect of PA (Figure 8D). It should
also be noted that the optimal concentrations of PA and LPA to stimulate DNA synthesis in
the myoblasts are similar (Figure 8E), also suggesting that the effect of PA is independent
of LPA formation. Lastly, myoblast proliferation was tested using synthetic PA that was
provided by Avanti Polar Lipids, who warrants a purity of the PA preparations higher
than 99%, and these preparations are not expected to contain any other lipid species. The
two different species of synthetic PA used in the experiments, 1,2-dipalmitoyl-sn-glycerol-
3-phosphate (16:0-PA) and 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate (16:0-18:1-PA),
stimulated myoblast proliferation to the same extent as the natural mixture of egg yolk PA
(Figure 8F), again suggesting that the stimulation of myoblast proliferation by PA is not
caused by contamination with LPA.
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are the mean ± SEM of 3 independent experiments performed in triplicate (**p<0.01, control versus PA-treated cells; *p 
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section. Results are expressed relative to the control value without agonist and are the mean ± SEM of 3 independent 
experiments performed in triplicate. (*p <0.05, control versus PA-treated cells in the absence or in the presence of the 
indicated inhibitors). C. Cells were labelled with 15 μM [14C]PA (0.05 μCi/mL) for the indicated time points. PA and LPA 
levels were determined as described in the Materials and Methods section. Results are expressed as percentage of the 
radioactivity present in the PA and LPA thin-layer chromatography (TLC) spots compared to that in total lipids and are 
the mean ± SEM of 3 independent experiments performed in duplicate. D. The cells were preincubated with 300 nM HA-
130 or 300 nM PF-8380 for 30 min before they were treated with 15 μM PA for 16 h. Cell proliferation was determined by 
staining the myoblasts with crystal violet as described in the Materials and Methods section. Results are expressed relative 
to the control value without agonist and are the mean ± SEM of 3 independent experiments performed in triplicate. (**p 
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cells versus PA-treated cells in the presence of this inhibitor; #p <0.05, control versus cells incubated with PF-8380). E. Cells 
Figure 8. PA-stimulated myoblast proliferation does not depend on conversion of PA to LPA. Myoblasts were serum-starved in DMEM supplemented with 0.1% BSA for 24 h. (A)
The cells were preincubated with 20 µM PACOCF3, 20 µM AACOCF3 or with 1 µM of the cPLA2 α inhibitor pyrrophenone (N-{(2S,4R)-4-(Biphenyl-2-ylmethyl-isobutyl-amino)-1-[2-
(2,4-difluorobenzoyl)-benzoyl]-pyrrolidin-2-ylmethyl}-3-[4-(2,4-dioxothiazoli in-5-ylidenem thyl)-phenyl] acrylamide) for 30 min before they were challenged with 15 µM PA for 16 h.
[3H]Thymidine incorporation into DNA was measured as described in the M terials and Methods section. R sul s are expressed relative to the control value without agonist and are the
mean ± SEM of 3 independent experiments performed in triplicate (** p < 0.01, control vers s PA-treated c lls; * p < 0.05, control versus PA-treated cells in the presence of the indicated
inhibitors. (B) Cells were treated as in panel A. Cell proliferation was determined by staining the myoblasts with crystal violet as described in the Materials and Methods section. Results
are expressed relative to the control value without agonist and are the mean ± SEM of 3 independent experiments performed in triplicate. (* p < 0.05, control versus PA-treated cells in the
absence or in the presence of the indicated inhibitors). (C) Cells were labelled w th 15 µM [14C]PA (0.05 µCi/mL) for th ndicated time points. PA and LPA levels were determined as
described in the Materials and Methods section. Results are expressed as percentage of he radio ctiv ty resent in the PA and LPA thin-layer chromatography (TLC) spots compared to
that in total lipids and are the mean ± SEM of 3 independent experiments performed in duplicate. (D) The cells were preincubated with 300 nM HA-130 or 300 nM PF-8380 for 30 min
before they were treated with 15 µM PA for 16 h. Cell proliferation was determined by staining the myoblasts with crystal violet as described in the Materials and Methods section. Results
are expressed relative to the control value without agonist and are the mean ± SEM of 3 independent experiments performed in triplicate. (** p < 0.01, control versus PA-treated cells; * p <
0.05, control versus PA-treated cells in the presence of HA-130, or PF-8380 treated cells versus PA-treated cells in the presence of this inhibitor; # p < 0.05, control versus cells incubated with
PF-8380). (E) Cells were treated with PA or LPA for 16 h at the indicated concentrations. [3H]Thymidine incorporation into DNA was measured as described in the Materials and Methods
section. Data are expressed relative to the control value without agonist and are the means ± SEM of 3 independent experiments performed in triplicate (*** p < 0.001, control versus PA- or
LPA-treated cells). (F) Cells treated with PA from egg yolk or with different PA species (at 15 µM), as indicated. Results are expressed relative to the control value without agonist and are
the mean ± SEM of 6 independent experiments performed in triplicate. (** p < 0.01, control versus PA from egg yolk; * p < 0.05, control versus 16:0-PA or 16:0-18:1-PA, as indicated).
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3. Discussion
Muscle development and regeneration after injury seem to follow the same procedures.
These rely on the activation of different cell types, namely satellite cells, and the formation
of new myofibers under the control of myogenic regulators, including mitogenic growth
factors or cytokines that are released by inflammatory cells [30–32]. However, the exact
functions and effects of these factors on muscle remodeling and how they have evolved are
not well understood. In the present work, we demonstrate that PA, a glycerophospholipid
with mitogenic properties, stimulates myoblast proliferation, and we have identified at least
part of the mechanisms by which PA regulates this process. Specifically, the treatment of
mouse myoblasts with PA, or with exogenous PLD to generate PA at the plasma membrane
of cells, resulted in the stimulation of the MEK/ERK1-2 and PI3K/Akt pathways leading to
myoblast proliferation. These findings are consistent with the PA myogenic stimulation of
mTOR, which is downstream of Akt or ERK1-2, in different cell types or tissues, including
skeletal muscle [13,18,33,34]. In a recent report, PA has also been demonstrated to stimulate
cell proliferation and promote G1/S phase transition through the activation of mTOR
in primary muscle cells of the fish turbot (Scophthalmus maximus) [35], which, given the
disparate growth pattern compared to mammals, suggests a well conserved action of PA
through evolution.
The rapid phosphorylation of Akt and ERK triggered by PA suggests that it may be a
receptor-mediated effect. In this regard, there is evidence suggesting that some PA actions
are elicited through interaction with G protein-coupled receptors [11,36–39]. Specifically,
the PA-stimulated Akt and ERK phosphorylation followed by the upregulation of DNA
synthesis and cell proliferation that we observed in this work were all inhibited by Ptx,
suggesting the intervention of Gi protein-coupled receptors in the regulation of these
processes. PA also stimulated actin polymerization within seconds, leading to human
monocyte migration, an effect that was optimal after 90 min of PA addition to the cells
and that was also inhibited by Ptx [40]. Although the concentrations of PA that stimulated
myoblast proliferation (10–15 µM) are higher than the PA concentrations found in plasma
(3 µM) [41], local PA concentrations may be increased under certain circumstances. In this
regard, the intracellular concentrations of PA in some cell types such as cardiomyocytes
are around 20 µM, and can be even higher in hepatocytes [42,43]; if these amounts of PA
were to be released upon cell activation, local concentrations of extracellular PA in the
range 10–15 µM would likely be achievable in vivo. In this connection, it has been shown
that 20 µM PA increases intracellular Ca2+ concentration through direct interaction with
LPA receptors [44], an action that is compatible with the stimulation of cell proliferation by
PA. Additionally, PA and phospholipase D2 (PLD2), a major enzyme that produces PA at
the plasma membrane of cells, are enriched in extracellular vesicles [45,46], which can be
secreted by most, if not all, cell types and bind to plasma membrane receptors to regulate
cell responses [47]. Moreover, the release or accumulation of these vesicles at specific
extracellular locations might increase extracellular PA concentrations locally.
Another key finding in the present study was that PA elicited its mitogenic effects in
the myoblasts through interaction with the LPA1 and LPA2 receptors in the absence of LPA
formation. In this connection, another study showed that the inhibition of LPA1/LPA3
receptors blocked PA induced morphological changes in C6 glioma cells [48]. In addition,
PA stimulated the migration of human neutrophils and human leukemia HL-60 monocytes,
and these actions could not be recapitulated by LPA [49]. Interestingly, LPA receptors
mediated the mitogenic action exerted by the bioactive sphingolipid ceramide 1-phosphate
through the stimulation of the LPA signaling axis [50]. In this work, a broader versatility of
these receptors in relation to receptor-ligand interaction is provided, being activated also
by PA. Moreover, as previously demonstrated in skeletal muscle precursor cells [26,51],
PA stimulated DNA synthesis with similar potency to that of LPA when administered at
the same concentrations, indicating that a possible contamination of the PA preparations
with LPA cannot account for the mitogenic effect of PA (if PA were to be contaminated by
LPA, 2% of the optimal concentration of PA used in this work (15 µM) would translate into
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a concentration equivalent to 0.3 µM LPA, which is not sufficient to stimulate myoblast
proliferation). Moreover, the inhibition of the two major enzymes for LPA formation,
PLA2 acting on PA or autotaxin acting on LPC, did not alter PA-stimulated cell prolif-
eration, and pure synthetic 16:0-PA and 16:0-18:1-PA also potently stimulated myoblast
proliferation. Additionally, the stimulation of human monocyte migration by suboptimal
concentrations of PA was 2-fold higher than similar concentrations of LPA [40], further
suggesting that at least some PA actions are independent of conversion to LPA. There are
at least two molecular models that can explain the possible interaction of PA with LPA
receptors. First, Alderton and co-workers suggested that both PA and LPA may bind to the
same receptors, with the additional acyl group in PA binding to a second site, through a
hydrophobic interaction. The ecto-site binding would effectively clamp PA to the receptor,
causing its activation. This site may be on the receptor itself or in the lipid milieu surround-
ing the receptor [52]. A second model would implicate the allosteric activation of the G
protein-coupled LPA receptors by PA. In fact, G protein-coupled receptors (GPCRs) have
been referred to as “allosteric machines” since they carry multiple, spatially distinct, yet
conformationally linked ligand-binding sites [53].
In addition to stimulating myoblast proliferation, PA also promotes muscle cell dif-
ferentiation [54–56]. Both cell proliferation and differentiation seem to be regulated by
mTOR, although through different mechanisms. In fact, mTORC1 can also be activated
by intracellular PA, independently of receptor interaction. Whilst PA-stimulated muscle
cell proliferation requires the upregulation of the kinase activity of mTORC1 [54,57], PA-
induced muscle cell differentiation is regulated by a kinase independent activity of mTOR,
probably involving the activation of Igf2 muscle specific enhancer gene [56].
In cell growth regulation, the amino acid-sensing Vps34-PLD1 pathway leads to the
direct activation of the mTORC1 kinase by PA [57,58], but the myogenic IGF-II pathway is
independent of mTOR kinase activity [56]. During myogenesis, myoblasts must exit the
cell cycle and undergo an ordered set of myogenic events. So, it may be speculated that PA
would first stimulate myoblast proliferation events that will be followed by the induction
of muscle cell differentiation into myocytes to promote myogenesis. These facts are in
agreement with previous work showing that PLD1- and PLD2-derived PA have different,
and at times opposed, effects in cell biology. In particular, whilst PLD1 deficiency impaired
FcεRI-mediated mast cell degranulation, PLD2 deficiency enhanced it [59]. Additionally,
PLD1 deficiency impaired F-actin disassembly, whereas PLD2 enhanced microtubule
formation [59].
It can be concluded that PA stimulates myoblast proliferation through interaction with
LPA1 and LPA2 receptors and the subsequent activation of the PI3K/Akt and MEK/ERK1-
2 pathways, independently of LPA formation. These findings place PA as a key regulator
of muscle regeneration and repair and may have a positive impact in ensuring healthy
musculature.
4. Materials and Methods
4.1. Materials
Phosphatidic acid (from egg yolk lecithin), lysophosphatidic acid, pertussis toxin, crystal
violet, SB21091, SP600125, LY294002, and PF-8380 (4-[3-(2,3-Dihydro-2-oxo-6-benzoxazolyl)-3-
oxopropyl]-1-piperazinecarboxylic acid (3,5-dichlorophenyl)methyl ester were from Sigma-
Aldrich (St Louis, MO, USA). Mouse skeletal muscle C2C12 cells were obtained from the
American Type Culture Collection (Manassas, VA, USA). Dulbecco’s modified eagle’s medium
(DMEM) was from Lonza. Fetal bovine serum (FBS), oligofectamine and OptiMEM medium
were supplied by Gibco (Thermo Fisher Scientific) (Waltham, MA, USA). [Methyl-3H] thymi-
dine, L-α-dipalmitoyl, phosphatidic acid, -[glycerol-14C(U)]-, and [oleoyl-9,10-3H]
-lysophosphatidic acid were from Perkin Elmer (Boston, MA, USA). Goat anti-rabbit IgG
horseradish peroxidase secondary antibody, and those to phospho-ERK1/2 (Thr-202/ Tyr-204),
phospho-Akt (Ser 473), total Akt, and total ERK1/2 were purchased from Cell Signalling
Technology (Beverly, MA, USA). The 10-DEBC hydrochloride and PLA2 inhibitors AACOCF3
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and PACOCF3 were supplied by Tocris Biosciences (Bristol, UK). HA-130 (B-[3-[[4-[[3-[(4-
Fluorophenyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenoxy]methyl]-phenyl]-
boronic acid was from Echelon Biosciences Inc (Salt Lake City, UT, USA). Antibodies and
small RNA interferences (siRNA) to LPA1-2 receptors, and the negative control siRNA, were
from Santa Cruz Biotechnology (Dallas, TX, USA). Small RNA interferences (siRNA) to PI3-
K, Akt and ERK1/2 were purchased from Ambion (Austin, TX, USA). PD98059 and the
cPLA2 α inhibitor pyrrophenone (N-{(2S,4R)-4-(Biphenyl-2-ylmethyl-isobutyl-amino)-1-[2-(2,4-
difluorobenzoyl)-benzoyl]-pyrrolidin-2-ylmethyl}-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-
phenyl] acrylamide) were from Calbiochem (San Diego, CA, USA). Sphingosine-1-phosphate,
N-palmitoyl-ceramide-1-phosphate (C1P), 1,2-dipalmitoyl-sn-glycerol-3-phosphate (16:0-PA),
1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate (16:0-18:1-PA) and the VPC32183 inhibitor were
supplied by Avanti Polar Lipids (Alabaster, AL, USA).
4.2. Cell Culture
C2C12 myoblasts (obtained from the American Type Culture Collection, ATCC CRL-
1772) were routinely grown in DMEM supplemented with 10% fetal bovine serum (FBS),
2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin in T75 tissue
culture flasks at 37 ◦C in an atmosphere of 5% CO2. The culture medium was replaced
every two days. The cells were passaged when about 70% confluent, taking care not to
surpass 20 passages, and were used in experiments when approximately 40–50% confluent.
The cells were serum-starved for 24 h in DMEM containing 1 mg/mL BSA prior to the
addition of agonists or inhibitors. PA was added to cells, sonicated in water so as to avoid
the use of organic solvents. When inhibitors were used, these were added to the cells 30
min prior to agonist addition.
4.3. Determination of DNA Synthesis
C2C12 cells were seeded and grown in 12-well plates at 20,000 cells/well, as indi-
cated above. Before experiments, the myoblasts were serum-starved for 24 h in DMEM
supplemented with 0.1% BSA, and were then incubated in the presence or absence of
agonists for 16 h. [3H]Thymidine incorporation into DNA was measured as described pre-
viously [60]. Briefly, [3H]thymidine (0.5 µCi/mL) was added for the last 2 h of incubation.
The medium was then removed and cells were washed twice with phosphate-buffered
saline (PBS). Cells were washed twice with ice-cold PBS before the addition of 500 µL
of 10% trichloroacetic acid for 5 min at 4 ◦C. The cells were washed again in ice-cold
PBS, and 250 µL of ethanol:ether (3:1 v/v) was added to the insoluble material. Samples
were then lysed in 0.25 M NaOH with 1% sodium dodecyl sulfate (SDS) for 1 h at 37 ◦C.
Radioactivity was measured by scintillation counting.
4.4. Determination of Cell Proliferation
C2C12 myoblasts were seeded at 4000 cells/well in 96-well plates, and were grown
and treated as indicated above. Before experiments, the myoblasts were serum-starved for
24 h in DMEM supplemented with 0.1% BSA, and were then incubated in the presence or
absence of agonists for 24 h. Cell proliferation was estimated by staining the cells with
crystal violet, as previously reported [61]. The crystal violet assay is a quick and reliable
screening method that is suitable to estimate cell number for the examination of cell growth
and survival [20,61,62]. Briefly, C2C12 myoblasts were stained with a solution of 0.5%
crystal violet in 20% methanol for 20 min at 37 ◦C. The cells were then washed three time
with PBS and left to dry. The dye was eluted by adding 200 µL of methanol to each well
with shaking for 20 min, and the absorbance was read at 570 nm using a Power Wave XS
plate reader from Biotek.
4.5. Small Interfering RNA (siRNA)-Mediated Depletion
C2C12 cells in OptiMEM were transfected with LPA1, LPA2, Akt, PI3-K, ERK1/2 or
negative vector siRNA (40 nM) for 5 h using oligofectamine according to the manufacturer’s
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instructions. The transfected cells were maintained in DMEM with 10% FBS for 48 h
before starting the experiments. In parallel, cell lysates were immunoblotted with specific
antibodies to evaluate the efficiency of siRNA-mediated protein depletion.
4.6. Western Blot Analysis
C2C12 myoblasts were collected and lysed in ice-cold homogenization buffer as previ-
ously described [63]. Protein aliquots (20–40 µg) from each sample were loaded onto 12%
polyacrylamide gels and separated by SDS-PAGE. Proteins were transferred to nitrocellu-
lose membranes and were blocked for 1 h with 5% skim milk in Tris-buffered saline (TBS)
containing 0.01% sodium azide (NaN3) and 0.1% Tween 20 to prevent non-specific antibody
binding. The nitrocellulose membranes were then incubated overnight at 4 ◦C with the
primary antibody dissolved in TBS/0.1% Tween. The nitrocellulose membranes were
then washed three times with TBS/0.1% Tween 20, and were incubated with horseradish
peroxidase-conjugated secondary antibody at 1:5000 dilution for 1 h. Protein bands were
visualized using the enhanced chemiluminescence assay kit, Supersignal West Femto
(from Pierce Biotechnology, Inc.).
4.7. Phosphatidic Acid Uptake and Metabolism
PA uptake by the myoblasts was studied by labelling C2C12 cells with 0.05 µCi/mL
(111,000 dpm) of [14C]PA at 15 µM for the indicated times. The radioactive medium was
then removed and the cells were washed twice with ice-cold calcium-free phosphate-
buffered saline (PBS). They were then scraped into 0.5 mL of methanol. The plates were
washed further with 0.5 mL of methanol, and the two methanol samples were combined and
mixed with 0.5 mL of chloroform. Lipids were extracted by separation of phases with 0.5 mL
of chloroform and 0.9 mL of a solution containing 2 M KCl in 0.2 M H3PO4. Chloroform
phases were dried down under a stream of nitrogen and lipids were separated by thin-
layer chromatography (TLC) using silica gel 60-coated plates. TLC plates were soaked in
2.3% boric acid in ethanol and developed with chloroform/ethanol/water/triethylamine
(30:35:8:35, v/v/v/v) and then dried. Positions of PA and LPA were identified after staining
with sulfuric acid in methanol by comparison with authentic standards. The radioactivity
was quantified by liquid scintillation counting after scraping the corresponding spots from
the TLC plates.
4.8. Preparation of Cell Membrane and LPA Radioligand-Binding Assay
The preparation of myoblast membranes and the LPA radioligand assay protocols
have been previously described [64]. Briefly, myoblasts were incubated in homogenization
buffer containing 10 mM Tris-HCl, 3 mM 2,2′,2”,2′′′-(Ethane-1,2-diyldinitrilo)tetraacetic
acid (EDTA), 3 mM Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid
(EGTA), 1mM NaF, protease inhibitors (10 µg/mL leupeptin, 10 µg/mL aprotinin, and
1 mM phenylmethylsulfonyl fluoride) for 30 min at pH 7.5 on ice. The myoblasts were
lysed using a Dounce homogenizer and were centrifuged at 500× g for 5 min to remove
unbroken cells and intact nuclei. Cell homogenates were then pelleted by centrifugation at
100,000× g for 30 min. The pellets were resuspended in a binding buffer containing 50 mM
Tris-HCl, 150 mM NaCl, 0.8% fatty acid-free bovine serum albumin (BSA), 10 µg/mL
leupeptin, 10 µg/mL aprotinin, and 0.2 mM phenylmethylsulfonyl fluoride, at pH 7.5.
Only freshly prepared membranes were used in experiments. [3H]LPA (22,000 dpm/assay
tube, at a final specific activity of 0.06 µCi/ pmol) and other lipids were sonicated in fatty
acid-free BSA binding buffer and mixed with the cell membrane samples in a volume of 150
µL. The binding assays were performed in borosilicate tubes at 37 ◦C for 30 min with gentle
mixing. The reactions were terminated by collecting the membranes onto glass monofiber
filters (GF/C with a 1225 Sampling Manifold from Millipore. The filters were rapidly
washed three times with 350 µL of ice-cold washing buffer containing 10 mM Tris-HCl and
15 mM NaCl, at pH 7.5. Radioactivity of filter-bound radionuclide was quantified by liquid
scintillation counting.
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4.9. Statistical Analysis
Results are expressed as means ± SEM of three independent experiments performed
in triplicate, unless indicated otherwise. Statistical analyses were performed using one-
way analysis of variance (ANOVA), or Student’s t-test as appropriate, with the level of
significance set at p < 0.05.
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